Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Levy

Allergy & Immunology Orange, CA Medical Doctor

NPI 1518055011 CMS profile 294997

705 W La Veta Ave, Ste 101, Orange, CA 92868

Open in the dashboard

General payments

$206,737

1,095 records reported · program years 2019–2025

Research payments

$117,151

Paid to them · 40 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$81,732 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Donald Levy of Orange, CA is reported in the CMS Open Payments database as having received $206,737 across 1,095 general payments and $117,151 in research payments paid to them. Separately, studies naming them as principal investigator received $81,732 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,661 182
2025 Research $22,196 9
2024 General $58,983 207
2024 Research $25,835 12
2023 General $17,976 204
2023 Research $29,401 3
2022 General $14,107 149
2021 General $20,218 144
2021 Research $39,000 1
2020 General $15,459 55
2020 Research $719 15
2019 General $42,334 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Levy
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Donald Levy were reported at $37,661. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Donald Levy Allergy & Immunology median Middle half National median
2019 $42,334 $594 $163–$1,512 $163
2020 $15,459 $426 $106–$1,233 $114
2021 $20,218 $638 $157–$1,708 $132
2022 $14,107 $790 $205–$1,961 $149
2023 $17,976 $852 $220–$2,147 $160
2024 $58,983 $865 $203–$2,267 $164
2025 $37,661 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CSL Behring $106,363 218 payments
  2. BioCryst US Sales Co., LLC $41,605 109 payments
  3. Shire North American Group Inc $16,247 35 payments
  4. BioCryst Pharmaceuticals, Inc. $12,150 35 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $10,013 97 payments
  6. Pharming Healthcare, Inc. $5,057 40 payments
  7. Genzyme Corporation $3,232 76 payments
  8. AstraZeneca Pharmaceuticals LP $2,320 99 payments
  9. GlaxoSmithKline, LLC. $1,723 107 payments
  10. Cycle Pharmaceuticals Inc $1,331 5 payments
  11. Other $6,695 274 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $99,848 75 payments
  2. Consulting Fee $39,153 23 payments
  3. Honoraria $26,540 14 payments
  4. Food and Beverage $25,495 914 payments
  5. Travel and Lodging $15,433 61 payments
  6. Education $268 8 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $35,528 110 payments
  2. Andembry $28,533 32 payments
  3. CINRYZE $17,051 22 payments
  4. Haegarda $13,067 61 payments
  5. Hizentra $8,465 25 payments
  6. Privigen $7,784 3 payments
  7. RUCONEST $5,057 40 payments
  8. TAKHZYRO $4,699 52 payments
  9. DUPIXENT $1,600 79 payments
  10. TRELEGY ELLIPTA $1,368 73 payments
  11. Other $12,848 501 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CSL Behring $117,151 40 payments

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,490

Median for Allergy/ Immunology: 449

Drug cost

$450,800

Median for Allergy/ Immunology: $169,700

Branded share of claims

34.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucala Mepolizumab Brand 14 $149,762
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 134 $95,129
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 17 $86,713
Spiriva Respimat Tiotropium Bromide Brand 41 $30,504
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 33 $29,663
Breo Ellipta Fluticasone/Vilanterol Brand 12 $8,228
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 17 $7,668
Incruse Ellipta Umeclidinium Bromide Brand 16 $5,535
Azelastine-Fluticasone Azelastine/Fluticasone Brand 39 $4,530
Azelastine Hcl Generic 158 $4,462

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$44,951

Medicare's payments for the services billed

Medicare patients

203

Average age 74

Services billed

1,772

120 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 58%
Diabetes 28%
Ischemic heart disease 26%
Osteoporosis 21%
Cancer 18%
Chronic kidney disease 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Orladeyo
$18,192 — —
Sajazir
$1,220 — —
RUCONEST
$554 — —
DUPIXENT
$537 — —
TRELEGY ELLIPTA
$329 134 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,135 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record